Trial
NCT03770728
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Hanmi Pharmaceutical Company Limited
Condition
Type 2 Diabetes Mellitus
Intervention
Efpeglenatide SAR439977
Why stopped
Sponsor decision to cancel TRIAL, not related to safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-02